查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403521

到 2030 年介入性肿瘤学市场预测：按产品、适应症、手术类型、最终用户和地区进行的全球分析

Interventional Oncology Market Forecasts to 2030 - Global Analysis By Product (Ablation Devices, Embolization Devices and Support Devices), Indication, Procedure Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球介入性肿瘤市场规模将达24亿美元，预计2030年将达到44亿美元，预测期内复合年增长率为8.8%。

在介入放射学领域，介入性肿瘤学着重于使用微创方法进行癌症检测和治疗。在这些手术中，将使用透视、磁振造影(MRI)、电脑断层扫描 (CT) 和超音波显像模式来指导工具定位并直接针对恶性提供标靶治疗。

根据美国癌症协会的数据，男性终生罹患乳癌的风险约为 833 分之一。因此，随着乳癌负担的增加，介入性肿瘤手术预计在预测期内会增加，这将推动市场成长。

对微创治疗的需求不断增长

由于患者和医疗保健专业人员对微创手术的需求不断增加，介入性肿瘤治疗的应用越来越广泛。与开放性手术相比，这些方法具有更快的恢復时间、更短的住院时间和更少的併发症。因此，某些癌症类型的治疗越来越多地转向介入性肿瘤学方法。朝向以患者为中心的医疗转变，即患者寻求恢復时间更短、副作用更少、生活品质更高的治疗方法，这与推动市场成长的微创手术是一致的。

缺乏合格的实验室技术人员

缺乏熟练的实验室专业人员可能会危及所提供的护理品质。拥有必要技能的专业人员对于准确无误地执行这些复杂的操作至关重要，而短缺可能会影响获得最佳结果的可用知识水平。在技​​术人员短缺的地区和医疗机构，患者接触肿瘤介入专家的机会可能有限。因此，患者接受微创癌症治疗的能力可能会受到这些获取差距的影响。

加大政府支持与报销政策

更好的报销指南和增加的政府支持可能会推动介入肿瘤治疗市场的发展。希望改善的经济奖励和保险覆盖范围将鼓励更多的提供者提供这些治疗并改善患者的可及性。由于报销规定的改善，寻求介入癌症治疗的患者可能面临更少的财务障碍。这将确保更多的患者能够获得这些治疗，更多的人能够获得尖端的微创癌症治疗。

医疗设备严格监管

由于满足严格的监管标准所需的大量测试、文件记录和合规程序，开发用于介入肿瘤学的新医疗设备可能成本高昂。愿意投资新技术研发的公司数量可能会因开发成本增加而受到阻碍。儘管这些法律的目的是保护患者，但它们也可能抑制新设备和技术进入市场，并可能延迟介入肿瘤治疗的发展。

COVID-19 的影响

由于担心在医疗环境中感染病毒，一些患者推迟了癌症治疗，特别是介入治疗，或完全寻求医疗协助。这种延迟可能妨碍了基本癌症治疗的及时开始或持续。为了减少住院时间和病毒感染的风险，肿瘤学家和其他医疗保健专业人员可能改变了治疗策略，倾向于全身药物和其他治疗方法而不是介入治疗。

预计在预测期内消融设备市场将是最大的

由于消融设备为治疗不同类型的肿瘤提供了一种侵入性较小的选择，因此预计这些设备的市场将增加收益。这些设备使用热、冷或其他能源来源来破坏肿瘤，而不是透过手术切除。这些消融装置用于介入性肿瘤治疗，例如安宁疗护、肿瘤缩小和肿瘤切除。与传统手术相比，它具有侵入性更小、恢復更快、併发症更少等优势，使其成为一些癌症患者的首选，并推动了市场的发展。

骨癌领域预计在预测期内复合年增长率最高。

骨癌的传统治疗方法包括手术、化疗，有时还包括放射线治疗。然而，介入性肿瘤学治疗方法在某些情况下或作为传统癌症治疗的补充可能有用。如果骨癌进展或引起问题，安宁疗护可能涉及介入治疗。例如，介入性放射治疗，例如肿瘤切除术（射频消融或冷冻），用于治疗疼痛或控制与骨转移相关的症状。

占比最大的地区：

亚太地区报告了大量癌症病例，其中一些国家的发生率很高。该地区的癌症发生率受到许多变数的影响，包括生活方式的改变、环境的变化和加强的癌症筛检计划。此外，透过将尖端介入肿瘤学技术（包括 MRI、CT 和超音波等影像方式）与最先进的仪器和设备相结合，可以提高癌症治疗的准确性、有效性和安全性。正在推动市场成长。

复合年增长率最高的地区：

在北美，市场受到完善的医疗系统、先进的技术开拓以及对微创癌症治疗需求不断增长的推动，因此预测期内的复合年增长率预计北美最高。此外，癌症发生率高、该地区完善的医疗保健系统、技术开拓以及对微创癌症治疗日益增长的需求是市场驱动因素。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球介入肿瘤学市场：按产品

  • 消融装置
    • 冷冻装置
    • 微波消融装置
    • 射频 (RF) 消融装置
    • 其他消融装置
  • 栓塞装置
    • 非放射性栓塞剂
      • 微球
      • 细颗粒
      • 涂层珠
      • 药物洗脱珠
    • 放射性栓塞材料
  • 支撑装置
    • 导管导引线
    • 微导管

第六章全球介入肿瘤学市场：依适应症分类

  • 肝细胞癌
  • 骨癌
  • 肾癌
  • 肺癌
  • 神经内分泌肿瘤
  • 多形性胶质母细胞瘤
  • 脾肿大
  • 转移性大肠直肠癌
  • 其他适应症

第七章全球介入肿瘤学市场：依手术类型

  • 经导管动脉栓塞
  • 经导管动脉栓塞
  • 肿瘤热消融术
  • 非热肿瘤消融
  • 经导管动脉栓塞
  • 其他治疗类型

第八章全球介入肿瘤学市场：依最终用户分类

  • 门诊手术中心
  • 研究和学术机构
  • 医院
  • 其他最终用户

第九章全球介入肿瘤学市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • AngioDynamics Inc.
  • Cook Medical
  • HealthTronics Inc.
  • Boston Scientific Corporation
  • Medtronic PLC
  • Terumo Corporation
  • Becton, Dickinson and Company
  • Merit Medical Systems Inc.
  • Profound Medical Corp.
  • IceCure Medical
  • Siemens Healthineers
  • Teleflex Incorporated
  • Medtronic Plc.
  • Alpinion Medical Systems Co.
  • IMBiotechnologies
  • Interface Biomaterials BV
  • Monteris Medical
  • Baylis Medical
  • Mermaid Medicals
  • Trod Medical
Product Code: SMRC24746

According to Stratistics MRC, the Global Interventional Oncology Market is accounted for $2.4 billion in 2023 and is expected to reach $4.4 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Within the area of interventional radiology, interventional oncology focuses on the use of minimally invasive methods for the detection and treatment of cancer. During these operations, imaging modalities including fluoroscopy, magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound are used to guide the positioning of tools and provide targeted therapies directly to malignancies.

According to the American Cancer Society, a man's lifetime risk of developing breast cancer is about 1 in 833. Hence, with the growing burden of breast cancer, interventional oncology procedures are expected to increase over the forecast period, which will drive growth in the market

Market Dynamics:

Driver:

Growing demand for minimally invasive therapeutics

Interventional oncology treatments are becoming more widely used as a result of patients' and healthcare professionals' growing demand for minimally invasive procedures. Compared to open operations, these methods provide quicker recovery periods, shorter hospital stays, and fewer problems. As a result, the treatment of some cancer types is increasingly moving toward interventional oncology techniques. The movement toward patient-centric care, in which patients look for therapies that provide shorter recovery periods, fewer side effects, and enhanced quality of life, is consistent with minimally invasive procedures which boost the market growth.

Restraint:

Lack of qualified laboratory personnel

The quality of care given might be jeopardized by a lack of skilled laboratory professionals. Professionals with the necessary skills are essential for carrying out these complex operations precisely and accurately, and a lack might impact the level of knowledge available to get the best results. Patients may have restricted access to specialist Interventional Oncology services in areas or healthcare settings where there is a shortage of skilled staff. Thus, the capacity of patients to get minimally invasive cancer therapies may be impacted by this gap in access.

Opportunity:

Increase in the government support and reimbursement policies

Better reimbursement guidelines and increased government assistance might propel the market for interventional oncology therapies forward. Better financial incentives and coverage are expected to encourage more healthcare providers to provide these therapies, increasing patient accessibility. Patients pursuing interventional cancer therapies may face less financial obstacles with improved reimbursement regulations. This may result in more patients having access to these treatments, guaranteeing that more people will have access to cutting-edge, minimally invasive cancer treatments.

Threat:

Stringent regulations for medical devices

Creating novel medical devices for interventional oncology may become quite expensive as a result of the considerable testing, paperwork, and compliance procedures needed to meet strict regulatory criteria. The number of businesses ready to invest in research and development for new technologies may be hampered by higher development expenses. Although the goal of these laws is to protect patients, they can also impede the introduction of novel devices and technologies into the market, which could postpone the development of interventional oncology therapies.

COVID-19 Impact

Fears of contracting the virus in medical settings caused some patients to postpone receiving cancer therapies, especially interventional procedures, or seeking medical assistance altogether. It's possible that this delay interfered with the timely start or continuation of essential cancer therapies. In order to reduce hospital stays or the risk of contracting the virus, oncologists and other healthcare professionals may have modified treatment strategies, preferring systemic medications or other forms of therapy over interventional procedures.

The ablation devices segment is expected to be the largest during the forecast period

Due to the fact that ablation devices provide less intrusive options for treating a variety of tumor types, the market for these devices is predicted to increase profitably. These devices destroy tumors by using heat, cold, or other energy sources instead of surgical excision. These ablation devices are used in palliative care, tumor reduction, and tumor ablation, among other interventional oncology therapies. Their advantages over traditional surgery, such as less invasiveness, faster recovery, and fewer complications, make them desirable options for some cancer patients and drive the market.

The osteosarcoma segment is expected to have the highest CAGR during the forecast period

The osteosarcoma segment is anticipated to witness the highest CAGR growth during the forecast period; surgery, chemotherapy, and sometimes radiation therapy are used in conjunction as the conventional treatment for osteosarcoma. Interventional oncology methods, however, could be useful in some situations or in addition to conventional cancer therapies. Palliative treatment may involve interventional therapies if the osteosarcoma has progressed or caused problems. To treat pain or control symptoms related to bone metastases, for example, interventional radiology procedures such as tumor ablation (radiofrequency or cryoablation) may be employed.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to A considerable number of cancer cases that are reported in Asia Pacific, with some of the region's nations having high incidence rates. The incidence of cancer in the area is influenced by a number of variables, including changes in lifestyle, alterations in the environment, and heightened cancer screening programs. Moreover the precision, effectiveness, and safety in cancer therapies are improved by the use of cutting-edge interventional oncology technology, including imaging modalities like MRI, CT, and ultrasound, in conjunction with cutting-edge instruments and equipment drives the growth of the market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the region's well-established healthcare system, technology developments, and the rising desire for minimally invasive cancer therapies are the main drivers of the market. Furthermore the high incidence of cancer, the region's well-established healthcare system, technology developments, and the rising desire for minimally invasive cancer therapies are the main drivers of the market.

Key players in the market:

Some of the key players profiled in the Interventional Oncology Market include AngioDynamics Inc., Cook Medical, HealthTronics Inc, Boston Scientific Corporation, Medtronic PLC, Terumo Corporation, Becton, Dickinson and Company, Merit Medical Systems Inc, Profound Medical Corp, IceCure Medical, Siemens Healthineers, Teleflex Incorporated, Medtronic Plc., Alpinion Medical Systems Co., IMBiotechnologies, Interface Biomaterials BV, Monteris Medical, Baylis Medical, Mermaid Medicals and Trod Medical

Key Developments:

In November 2023, Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept® Intraosseous Nerve Ablation System, a therapy to treat vertebrogenic pain that is a form of chronic low back pain.

In September 2023, Medtronic plc announced CE (Conformite Europeenne) Mark approval for its new all-in-one, disposable Simplera™ continuous glucose monitor (CGM) featuring a simple, two-step insertion process.

In July 2023, Purdue, IU and Cook Medical partner for 3-pronged approach to improve pediatric care. The Crossroads Pediatric Device Consortium will focus on meeting unmet needs for pediatric patients by accelerating the development, approval and availability of innovative medical devices for children.

Products Covered:

  • Ablation Devices
  • Embolization Devices
  • Support Devices

Indications Covered:

  • Hepatocellular Carcinoma
  • Osteosarcoma
  • Renal Cancer
  • Lung Cancer
  • Neuroendocrine Tumor
  • Glioblastoma Multiforme
  • Splenomegaly
  • Metastatic Colorectal Cancer
  • Other Indications

Procedure Types Covered:

  • Transcatheter Arterial Radioembolization
  • Transcatheter Arterial Chemoembolization
  • Thermal Tumor Ablation
  • Non-Thermal Tumor Ablation
  • Transcatheter Arterial Embolization
  • Other Procedure Types

End Users Covered:

  • Ambulatory Surgery Centers
  • Research & Academic Institutes
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Interventional Oncology Market, By Product

  • 5.1 Introduction
  • 5.2 Ablation Devices
    • 5.2.1 Cryoablation Devices
    • 5.2.2 Microwave Ablation Devices
    • 5.2.3 Radiofrequency (RF) Ablation Devices
    • 5.2.4 Other Ablation Devices
  • 5.3 Embolization Devices
    • 5.3.1 Non-Radio embolic Agents
      • 5.3.1.1 Microspheres
      • 5.3.1.2 Microparticles
      • 5.3.1.3 Coated Beads
      • 5.3.1.4 Drug Eluting Beads
    • 5.3.2 Radioembolic Agents
  • 5.4 Support Devices
    • 5.4.1 Guidewires
    • 5.4.2 Microcatheters

6 Global Interventional Oncology Market, By Indication

  • 6.1 Introduction
  • 6.2 Hepatocellular Carcinoma
  • 6.3 Osteosarcoma
  • 6.4 Renal Cancer
  • 6.5 Lung Cancer
  • 6.6 Neuroendocrine Tumor
  • 6.7 Glioblastoma Multiforme
  • 6.8 Splenomegaly
  • 6.9 Metastatic Colorectal Cancer
  • 6.10 Other Indications

7 Global Interventional Oncology Market, By Procedure Type

  • 7.1 Introduction
  • 7.2 Transcatheter Arterial Radioembolization
  • 7.3 Transcatheter Arterial Chemoembolization
  • 7.4 Thermal Tumor Ablation
  • 7.5 Non-Thermal Tumor Ablation
  • 7.6 Transcatheter Arterial Embolization
  • 7.7 Other Procedure Types

8 Global Interventional Oncology Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgery Centers
  • 8.3 Research & Academic Institutes
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Interventional Oncology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AngioDynamics Inc.
  • 11.2 Cook Medical
  • 11.3 HealthTronics Inc.
  • 11.4 Boston Scientific Corporation
  • 11.5 Medtronic PLC
  • 11.6 Terumo Corporation
  • 11.7 Becton, Dickinson and Company
  • 11.8 Merit Medical Systems Inc.
  • 11.9 Profound Medical Corp.
  • 11.10 IceCure Medical
  • 11.11 Siemens Healthineers
  • 11.12 Teleflex Incorporated
  • 11.13 Medtronic Plc.
  • 11.14 Alpinion Medical Systems Co.
  • 11.15 IMBiotechnologies
  • 11.16 Interface Biomaterials BV
  • 11.17 Monteris Medical
  • 11.18 Baylis Medical
  • 11.19 Mermaid Medicals
  • 11.20 Trod Medical

List of Tables

  • Table 1 Global Interventional Oncology Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Interventional Oncology Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Interventional Oncology Market Outlook, By Ablation Devices (2021-2030) ($MN)
  • Table 4 Global Interventional Oncology Market Outlook, By Cryoablation Devices (2021-2030) ($MN)
  • Table 5 Global Interventional Oncology Market Outlook, By Microwave Ablation Devices (2021-2030) ($MN)
  • Table 6 Global Interventional Oncology Market Outlook, By Radiofrequency (RF) Ablation Devices (2021-2030) ($MN)
  • Table 7 Global Interventional Oncology Market Outlook, By Other Ablation Devices (2021-2030) ($MN)
  • Table 8 Global Interventional Oncology Market Outlook, By Embolization Devices (2021-2030) ($MN)
  • Table 9 Global Interventional Oncology Market Outlook, By Non-Radio embolic Agents (2021-2030) ($MN)
  • Table 10 Global Interventional Oncology Market Outlook, By Microspheres (2021-2030) ($MN)
  • Table 11 Global Interventional Oncology Market Outlook, By Microparticles (2021-2030) ($MN)
  • Table 12 Global Interventional Oncology Market Outlook, By Coated Beads (2021-2030) ($MN)
  • Table 13 Global Interventional Oncology Market Outlook, By Drug Eluting Beads (2021-2030) ($MN)
  • Table 14 Global Interventional Oncology Market Outlook, By Radioembolic Agents (2021-2030) ($MN)
  • Table 15 Global Interventional Oncology Market Outlook, By Support Devices (2021-2030) ($MN)
  • Table 16 Global Interventional Oncology Market Outlook, By Guidewires (2021-2030) ($MN)
  • Table 17 Global Interventional Oncology Market Outlook, By Microcatheters (2021-2030) ($MN)
  • Table 18 Global Interventional Oncology Market Outlook, By Indication (2021-2030) ($MN)
  • Table 19 Global Interventional Oncology Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
  • Table 20 Global Interventional Oncology Market Outlook, By Osteosarcoma (2021-2030) ($MN)
  • Table 21 Global Interventional Oncology Market Outlook, By Renal Cancer (2021-2030) ($MN)
  • Table 22 Global Interventional Oncology Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 23 Global Interventional Oncology Market Outlook, By Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 24 Global Interventional Oncology Market Outlook, By Glioblastoma Multiforme (2021-2030) ($MN)
  • Table 25 Global Interventional Oncology Market Outlook, By Splenomegaly (2021-2030) ($MN)
  • Table 26 Global Interventional Oncology Market Outlook, By Metastatic Colorectal Cancer (2021-2030) ($MN)
  • Table 27 Global Interventional Oncology Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 28 Global Interventional Oncology Market Outlook, By Procedure Type (2021-2030) ($MN)
  • Table 29 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Radioembolization (2021-2030) ($MN)
  • Table 30 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Chemoembolization (2021-2030) ($MN)
  • Table 31 Global Interventional Oncology Market Outlook, By Thermal Tumor Ablation (2021-2030) ($MN)
  • Table 32 Global Interventional Oncology Market Outlook, By Non-Thermal Tumor Ablation (2021-2030) ($MN)
  • Table 33 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Embolization (2021-2030) ($MN)
  • Table 34 Global Interventional Oncology Market Outlook, By Other Procedure Types (2021-2030) ($MN)
  • Table 35 Global Interventional Oncology Market Outlook, By End User (2021-2030) ($MN)
  • Table 36 Global Interventional Oncology Market Outlook, By Ambulatory Surgery Centers (2021-2030) ($MN)
  • Table 37 Global Interventional Oncology Market Outlook, By Research & Academic Institutes (2021-2030) ($MN)
  • Table 38 Global Interventional Oncology Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 39 Global Interventional Oncology Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.